Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Mark Brugh"'
Autor:
Kevin T. Bennett, Sharon E. Bone, Andrew C. Akin, Eva R. Birnbaum, Anastasia V. Blake, Mark Brugh, Scott R. Daly, Jonathan W. Engle, Michael E. Fassbender, Maryline G. Ferrier, Stosh A. Kozimor, Laura M. Lilley, Christopher A. Martinez, Veronika Mocko, Francois M. Nortier, Benjamin W. Stein, Sara L. Thiemann, Christiaan Vermeulen
Publikováno v:
ACS Central Science, Vol 5, Iss 3, Pp 494-505 (2019)
Externí odkaz:
https://doaj.org/article/116aeabb09ca4141a5f9a9981eb10e94
Autor:
Tara Mastren, Valery Radchenko, Allison Owens, Roy Copping, Rose Boll, Justin R. Griswold, Saed Mirzadeh, Lance E. Wyant, Mark Brugh, Jonathan W. Engle, Francois M. Nortier, Eva R. Birnbaum, Kevin D. John, Michael E. Fassbender
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
Abstract A new method has been developed for the isolation of 223,224,225Ra, in high yield and purity, from a proton irradiated 232Th matrix. Herein we report an all-aqueous process using multiple solid-supported adsorption steps including a citrate
Externí odkaz:
https://doaj.org/article/c4ce5e09c2234701ae14e728aa214ee6
Autor:
Tara Mastren, Valery Radchenko, Philip D Hopkins, Jonathan W Engle, John W Weidner, Roy Copping, Mark Brugh, F Meiring Nortier, Eva R Birnbaum, Kevin D John, Michael Ernst-Heinrich Fassbender
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0190308 (2017)
Ruthenium-103 is the parent isotope of 103mRh (t1/2 56.1 min), an isotope of interest for Auger electron therapy. During the proton irradiation of thorium targets, large amounts of 103Ru are generated through proton induced fission. The development o
Externí odkaz:
https://doaj.org/article/eb2b44ace77b4b0190e5973af9c40b82
Autor:
D. Scott Wilbur, Andrew C. Akin, Eva R. Birnbaum, Mark Brugh, Michael E. Fassbender, Kevin D. John, Tara Mastren, Francois M. Nortier, Roy Copping
Publikováno v:
Nuclear Medicine and Biology. :69-73
Purpose Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Due to its short half-life, 226Th must be provided through a radionuclide generator system from its parent 230U (20.8 d). Furthermore
Autor:
Eva R. Birnbaum, Yawen Li, Andrew C. Akin, David H. Woen, Kevin T. Bennett, Donald K. Hamlin, Veronika Mocko, Eric Dorman, D. Scott Wilbur, Stosh A. Kozimor, Nickolas H. Anderson, Frankie D. White, Elodie Dalodière, Cecilia Eiroa-Lledo, Mark Brugh, Laura M. Lilley, Sara L. Thiemann, Maryline G. Ferrier, Anastasia V. Blake
Publikováno v:
Inorganic Chemistry. 59:6137-6146
Increasing access to the short-lived α-emitting radionuclide astatine-211 (211At) has the potential to advance targeted α-therapeutic treatment of disease and to solve challenges facing the medical...
Autor:
Meiring F. Nortier, Tara Mastren, Eva R. Birnbaum, C. Vermeulen, Mark Brugh, Michael E. Fassbender
Publikováno v:
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 443:1-4
The degradation of proton beam energy within a target stack was monitored via product nuclide ratios at the Los Alamos Isotope Production Facility (LANL-IPF). Nuclear reaction channels employed as energy monitors included NatNi(p,x)57Co and NatNi(p,x
Autor:
Scott R. Daly, Kevin T. Bennett, Francois M. Nortier, Sharon E. Bone, Laura M. Lilley, C. Vermeulen, Veronika Mocko, Anastasia V. Blake, Benjamin W. Stein, Eva R. Birnbaum, Sara L. Thiemann, Christopher A. Martinez, Michael E. Fassbender, Maryline G. Ferrier, Jonathan W. Engle, Mark Brugh, Andrew C. Akin, Stosh A. Kozimor
Publikováno v:
ACS Central Science, Vol 5, Iss 3, Pp 494-505 (2019)
ACS Central Science
ACS Central Science
Radionuclides find widespread use in medical technologies for treating and diagnosing disease. Among successful and emerging radiotherapeutics, 119Sb has unique potential in targeted therapeutic applications for low-energy electron-emitting isotopes.
Autor:
Tara, Mastren, Andrew, Akin, Roy, Copping, Mark, Brugh, D Scott, Wilbur, Eva R, Birnbaum, Francois M, Nortier, Kevin D, John, Michael E, Fassbender
Publikováno v:
Nuclear medicine and biology.
Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Due to its short half-life,A reverse radionuclide generator system was developed employing a DGA extraction chromatography column. AThorium-2
Autor:
Mitchell T, Friend, T Gannon, Parker, Tara, Mastren, Veronika, Mocko, Mark, Brugh, Eva R, Birnbaum, Michael E, Fassbender
Publikováno v:
Journal of chromatography. A. 1624
The alpha-emitter
Autor:
Tyler A, Bailey, Veronika, Mocko, Katherine M, Shield, Dahlia D, An, Andrew C, Akin, Eva R, Birnbaum, Mark, Brugh, Jason C, Cooley, Jonathan W, Engle, Michael E, Fassbender, Stacey S, Gauny, Andrew L, Lakes, Francois M, Nortier, Ellen M, O'Brien, Sara L, Thiemann, Frankie D, White, Christiaan, Vermeulen, Stosh A, Kozimor, Rebecca J, Abergel
Publikováno v:
Nature chemistry. 13(3)
Developing targeted α-therapies has the potential to transform how diseases are treated. In these interventions, targeting vectors are labelled with α-emitting radioisotopes that deliver destructive radiation discretely to diseased cells while simu